An RNAi reagent and a medicine that have no adverse effects such as interferon and/or cytotoxicity induction are provided. An shRNA used for sequence-specific RNA interference without interferon and/or cytotoxicity induction and a medicine and a reagent containing the shRNA are provided, such shRNA comprising a sense strand comprising a sequence homologous to a target sequence of the target mRNA and an antisense strand comprising a sequence complementary to the sequence of the sense strand and having an overhang comprising one or a plurality of G(s) at the 5' end of the sense strand.